Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 18 | 2024 | 409 | 6.210 |
Why?
|
| Mastectomy | 7 | 2023 | 36 | 1.590 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 18 | 1.220 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 172 | 1.030 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2022 | 3 | 0.820 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2022 | 12 | 0.810 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2022 | 18 | 0.770 |
Why?
|
| Mammaplasty | 1 | 2021 | 6 | 0.750 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 381 | 0.730 |
Why?
|
| Female | 19 | 2024 | 15212 | 0.710 |
Why?
|
| Retrospective Studies | 10 | 2023 | 3538 | 0.670 |
Why?
|
| Hypercalcemia | 1 | 2019 | 9 | 0.630 |
Why?
|
| Carcinoma, Ductal | 1 | 2019 | 5 | 0.630 |
Why?
|
| Breast Neoplasms, Male | 1 | 2019 | 11 | 0.620 |
Why?
|
| Referral and Consultation | 2 | 2021 | 88 | 0.620 |
Why?
|
| Tamoxifen | 1 | 2019 | 30 | 0.610 |
Why?
|
| Humans | 21 | 2024 | 27072 | 0.600 |
Why?
|
| Stromal Cells | 1 | 2018 | 34 | 0.590 |
Why?
|
| Disease Management | 2 | 2019 | 102 | 0.590 |
Why?
|
| Mastectomy, Segmental | 2 | 2024 | 29 | 0.580 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 10 | 0.570 |
Why?
|
| Patient Compliance | 1 | 2018 | 150 | 0.550 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 111 | 0.550 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2016 | 4 | 0.530 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 30 | 0.520 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 261 | 0.520 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 30 | 0.520 |
Why?
|
| Body Mass Index | 1 | 2019 | 458 | 0.510 |
Why?
|
| Obesity | 1 | 2019 | 311 | 0.500 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 86 | 0.490 |
Why?
|
| Carcinoma, Lobular | 1 | 2015 | 23 | 0.470 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2015 | 33 | 0.470 |
Why?
|
| Aged | 7 | 2023 | 8997 | 0.450 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2015 | 164 | 0.440 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2024 | 23 | 0.420 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 363 | 0.420 |
Why?
|
| Decision Making | 1 | 2015 | 223 | 0.400 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 4777 | 0.400 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 80 | 0.390 |
Why?
|
| Oocytes | 2 | 2009 | 7 | 0.370 |
Why?
|
| Cryopreservation | 2 | 2009 | 15 | 0.370 |
Why?
|
| Postoperative Complications | 1 | 2016 | 916 | 0.330 |
Why?
|
| Case-Control Studies | 2 | 2023 | 587 | 0.310 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2008 | 1 | 0.290 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1792 | 0.290 |
Why?
|
| Infertility, Female | 1 | 2007 | 22 | 0.280 |
Why?
|
| Quality of Life | 2 | 2022 | 629 | 0.270 |
Why?
|
| Adult | 7 | 2022 | 7831 | 0.260 |
Why?
|
| Prognosis | 2 | 2019 | 785 | 0.230 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2023 | 16 | 0.210 |
Why?
|
| Time Factors | 4 | 2019 | 1433 | 0.200 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 102 | 0.190 |
Why?
|
| Mutation | 1 | 2023 | 348 | 0.190 |
Why?
|
| Length of Stay | 1 | 2023 | 313 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2024 | 211 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 81 | 0.170 |
Why?
|
| Middle Aged | 4 | 2023 | 8923 | 0.170 |
Why?
|
| Acellular Dermis | 1 | 2019 | 7 | 0.160 |
Why?
|
| Breast Implantation | 1 | 2019 | 4 | 0.160 |
Why?
|
| Breast Implants | 1 | 2019 | 7 | 0.160 |
Why?
|
| Mammography | 1 | 2019 | 47 | 0.160 |
Why?
|
| Treatment Outcome | 2 | 2019 | 3485 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 300 | 0.150 |
Why?
|
| Phyllodes Tumor | 1 | 2017 | 2 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2017 | 13 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2016 | 54 | 0.130 |
Why?
|
| Needles | 1 | 2016 | 20 | 0.130 |
Why?
|
| Age Factors | 1 | 2018 | 766 | 0.120 |
Why?
|
| Biopsy | 1 | 2015 | 201 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 370 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 1112 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 683 | 0.090 |
Why?
|
| Young Adult | 1 | 2016 | 1994 | 0.080 |
Why?
|
| Amenorrhea | 1 | 2009 | 2 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 25 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 198 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2007 | 19 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2008 | 227 | 0.060 |
Why?
|
| Breast | 1 | 2024 | 28 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2024 | 79 | 0.050 |
Why?
|
| General Surgery | 1 | 2024 | 54 | 0.050 |
Why?
|
| Curriculum | 1 | 2024 | 138 | 0.050 |
Why?
|
| Male | 1 | 2019 | 14772 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2024 | 206 | 0.050 |
Why?
|
| Adolescent | 1 | 2008 | 2172 | 0.050 |
Why?
|
| Radiologists | 1 | 2019 | 8 | 0.040 |
Why?
|
| Esthetics | 1 | 2019 | 13 | 0.040 |
Why?
|
| Pectoralis Muscles | 1 | 2019 | 18 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 32 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 41 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 91 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 123 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2019 | 135 | 0.040 |
Why?
|
| Wound Healing | 1 | 2019 | 153 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 195 | 0.040 |
Why?
|
| Surgeons | 1 | 2019 | 87 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 420 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 347 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 624 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2019 | 523 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1890 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 65 | 0.020 |
Why?
|